Brief: Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing
18/11/2025 11:08
Nov 18 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILING DERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILING DERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE Further company coverage: DRMA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview